共 41 条
Toll-Like Receptor 9 Inhibition Confers Protection from Liver Ischemia-Reperfusion Injury
被引:166
作者:
Bamboat, Zubin M.
[1
]
Balachandran, Vinod P.
[1
]
Ocuin, Lee M.
[1
]
Obaid, Hebroon
[1
]
Plitas, George
[1
]
DeMatteo, Ronald P.
[1
]
机构:
[1] Mem Sloan Kettering Canc Ctr, Hepatopancreatobiliary Serv, New York, NY 10065 USA
来源:
基金:
美国国家卫生研究院;
关键词:
HEPATIC ISCHEMIA/REPERFUSION INJURY;
SYSTEMIC AUTOIMMUNE-DISEASE;
BACTERIAL-DNA;
CPG MOTIFS;
RAT-LIVER;
ENDOSOMAL TRANSLOCATION;
MONOCLONAL-ANTIBODY;
ENDOTHELIAL-CELLS;
DENDRITIC CELLS;
ACTIVATION;
D O I:
10.1002/hep.23365
中图分类号:
R57 [消化系及腹部疾病];
学科分类号:
摘要:
Endogenous ligands such as high-mobility group box 1 (HMGB1) and nucleic acids are released by dying cells and bind Toll-like receptors (TLRs). Because TLR9 sits at the interface of microbial and sterile inflammation by detecting both bacterial and endogenous DNA, we investigated its role in a model of segmental liver ischemia-reperfusion (I/R) injury. Mice were subjected to I hour of ischemia and 12 hours of reperfusion before assessment of liver injury, cytokines, and reactive oxygen species (ROS). Wild-type (WT) mice treated with an inhibitory cytosine-guanosine dinucleotide (iCpG) sequence and TLR9(-/-) mice had markedly reduced serum alanine aminotransferase (ALT) and inflammatory cytokines after liver I/R. Liver damage was mediated by bone marrow-derived cells because WT mice transplanted with TLR9(-/-) bone marrow were protected from hepatic I/R injury. Injury in WT mice partly depended on TLR9 signaling in neutrophils, which enhanced production of ROS, interleukin-6 (IL-6), and tumor necrosis factor (TNF). In vitro, DNA released from necrotic hepatocytes increased liver nonparenchymal cell (NPC) and neutrophil cytokine secretion through a TLR9-dependent mechanism. Inhibition of both TLR9 and HMGB1 caused maximal inflammatory cytokine suppression in neutrophil cultures and conferred even greater protection from I/R injury in vivo. Conclusion: TLR9 serves as an endogenous sensor of tissue necrosis that exacerbates the innate immune response during liver I/R. Combined blockade of TLR9 and HMGB1 represents a clinically relevant, novel approach to limiting I/R injury. (HEPATOLOGY 2010;51:621-632.)
引用
收藏
页码:621 / 632
页数:12
相关论文